RE: Rns Out10 Mar 2026 07:22
Anthony Tennyson, Chief Executive Officer of Solvonis, added: "The selection of SVN-114 as the lead candidate from our PTSD discovery programme highlights the strength of Solvonis' proprietary CNS discovery platform.
"Importantly, this compound emerges from a chemical series supported by international composition-of-matter patent applications, providing a strong intellectual property foundation and long-term commercial potential.
"PTSD represents a major global mental health challenge affecting millions of people and remains an area of significant unmet medical need. We believe SVN-114 has the potential to offer a differentiated therapeutic approach in this area."
Who is selling now?